SABCS program director Kate Lathrop, MD, talks with Komal Jhaveri, MD, FACP, about the results of phase 3 EMBER-3 trial, which evaluated the role of imlunestrant as monotherapy or in combination with abemaciclib in patients with ER+, HER2- advanced breast cancer whose disease had recurred or progressed during or after an aromatase inhibitor alone or with a CDK4/6 inhibitor.